KRAS and colorectal carcinoma: MiR-143 inhibits key targets essential for CRC growth such as the GTPase KRAS, the DNA (cytosine-5)-methyltransferase 3A (DNMT3A), the receptor tyrosine-protein kinase erbB-3, and the mitogen-activated protein kinase 7 (MAPK7) [31,32].